<DOC>
	<DOC>NCT00795925</DOC>
	<brief_summary>The open-label dose-escalating two-centre study was designed to assess the pharmacokinetics as well as safety, tolerability and efficacy parameters of propiverine in patients 5-10 years of age suffering from frequency-urgency-syndrome and urinary incontinence indicative of detrusor overactivity (overactive bladder) for determination of the recommended dose in children.</brief_summary>
	<brief_title>Dose-Escalating Study of Propiverine Hydrochloride in Children Suffering From Overactive Bladder</brief_title>
	<detailed_description />
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Propiverine</mesh_term>
	<criteria>Main Micturition Frequency ≥6 micturitions during awake period Urge Incontinence Episodes ≥1/week Urgency Episodes ≥1/day Main Contraindication to anticholinergic therapy Repeated measurement of Post Void Residual ≥20 mL Nocturnal Enuresis Clinically significant cardiovascular, hepatic, renal, gastrointestinal or hematological disease, psychiatric disorder or diabetes insipidus Anatomical abnormalities of the urinary tract</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>propiverine</keyword>
	<keyword>anticholinergics</keyword>
	<keyword>urinary incontinence</keyword>
	<keyword>overactive bladder</keyword>
	<keyword>children</keyword>
	<keyword>dose-finding in children aged 5-10 years</keyword>
</DOC>